Expansions of T-cell Subsets Expressing Particular T ... - ATS Journals

9 downloads 0 Views 132KB Size Report
Feb 13, 2013 - choalveolar lavage in a patient with chronic berylliosis: evidence for hyper- sensitivity pneumonitis. Ann. Intern. Med. 97:213–216. 10. Tinkle ...
Expansions of T-cell Subsets Expressing Particular T-cell Receptor Variable Regions in Chronic Beryllium Disease Andrew P. Fontenot, Brian L. Kotzin, Christine E. Comment, and Lee S. Newman Departments of Medicine and Pediatrics, National Jewish Medical and Research Center; and Departments of Medicine, Preventive Medicine and Biometrics, and Immunology, University of Colorado Health Sciences Center, Denver, Colorado

Chronic beryllium disease (CBD) is a granulomatous disorder characterized by the presence of noncaseating granulomas and mononuclear cell inflammation, occurring in 1 to 5% of people exposed to beryllium in the workplace. In the lungs of affected patients, CD41 T cells accumulate. Using anti-T-cell receptor (TCR) monoclonal antibodies, we investigated the TCR beta and alpha variable (Vb and Va, respectively) repertoire in the bronchoalveolar lavage (BAL) and blood of both CBD patients and healthy controls. There was marked heterogeneity within the BAL CD41 T-cell repertoire in both patients and controls. However, 11 of the 28 CBD patients demonstrated 16 different T-cell subset expansions within the BAL as compared with only one expansion in ten healthy controls. Five of the 16 expansions in CBD patients expressed Vb3. Altered TCR expression within the BAL T-cell repertoire appeared to persist over time in patients who underwent repeat evaluation. After in vitro stimulation of BAL T cells with beryllium sulfate and interleukin-2, we noted further alteration of the BAL TCR repertoire in some individuals. These results provide additional insight into the involvement of CD41 T cells in this disease and form the basis for studies to examine the nature of the stimulating antigen. Fontenot, A. P., B. L. Kotzin, C. E. Comment, and L. S. Newman. 1998. Expansions of T-cell subsets expressing particular T-cell receptor variable regions in chronic beryllium disease. Am. J. Respir. Cell Mol. Biol. 18:581–589.

Chronic beryllium disease (CBD) is a granulomatous disorder that develops in 1 to 5% of individuals exposed to beryllium in the aerospace, automotive, ceramics, electronics, and defense industries (1–5). The lung is the predominant organ involved, although the lymphatic system, skin, liver, and spleen may also be affected by the granulomatous inflammation (4, 5). The diagnosis of CBD requires an exposure history, the presence of noncaseating granulomas and mononuclear cell inflammation in a lung biopsy specimen, and a positive in vitro proliferative response of peripheral blood or bronchoalveolar lavage (BAL) T cells to beryllium salts (6). Evidence suggests that CD41 T cells are important in initiating and perpetuating the immune response to beryllium (1, 7–10), and that the in vitro T-cell response to beryllium sulfate (BeSO4) is class II major histocompatibility complex (MHC) antigen (Received in original form April 4, 1997 and in revised form July 30, 1997) Address correspondence to: Lee S. Newman, National Jewish Medical and Research Center, 1400 Jackson St., Room G010, Denver, CO 80206. E-mail: [email protected] Abbreviations: bronchoalveolar lavage, BAL; beryllium sulfate, BeSO 4; chronic beryllium disease, CBD; human leukocyte antigen, HLA; interleukin, IL; monoclonal antibodies, mAb; major histocompatibility complex, MHC; T-cell receptor, TCR; variable, V. Am. J. Respir. Cell Mol. Biol. Vol. 18, pp. 581–589, 1998

restricted (1, 2). The nature of the antigen that interacts with the T-cell receptor (TCR) and MHC is not known. Pulmonary lesions in sarcoidosis and CBD are histologically indistinguishable (11), but the etiology of sarcoidosis is unknown. These diseases also display similar BAL abnormalities with regard to increased total white-cell and T-cell numbers and CD4 1 T-cell enrichment. Studies in sarcoidosis have demonstrated CD41 T-cell expansions in the BAL that express particular TCR variable (V) regions. Although the Vb and Va regions expressed by the expanded subset(s) varied among different individual sarcoidosis patients, a trend for increased usage of V b8 and Va2.3 was reported in some studies (12–14). Junctional region sequencing showed that the expanded subsets were clonal or oligoclonal in origin, consistent with stimulation by conventional antigen in the lung. We hypothesized that selective T-cell expansions would also characterize BAL CD41 T cells in CBD and that V region expression would be different and more uniform compared with sarcoidosis. In the present work, we demonstrate skewing of the TCR Vb repertoire in the BAL compared with the blood of patients with CBD and with healthy controls. Approximately one-third of the T-cell expansions identified in the BAL of the different patients expressed Vb3, and overall, the repertoire alterations appeared to be distinct from that previously reported in sarcoidosis. Alterations of CD4 1

582

AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY VOL. 18 1998

TCR expression tended to persist in BAL over time and, in some cases, could be further enhanced by in vitro stimulation with beryllium salts. These findings suggest that beryllium-activated CD41 T cells accumulate and persist in the lungs of patients with CBD, and are likely to be important in the pathogenesis of this disease.

Materials and Methods Study Population The diagnosis of CBD was established in 28 patients (age 50 6 2.1 yr; 20 men, 8 women; 13 never smokers, 2 current smokers, 13 former smokers) by using previously defined criteria (6, 15), including the presence of granulomatous inflammation in lung biopsies, a beryllium exposure history, and a positive BAL lymphocyte proliferative response to BeSO4. Exposure to beryllium occurred in the following circumstances: ceramics industry (n 5 14), nuclear weapons plant (n 5 13), and other (n 5 1). The patients with CBD included 19 initially asymptomatic individuals who were diagnosed through screening programs. Three of these individuals subsequently became symptomatic. In addition, nine individuals were initially evaluated after the development of symptoms. The presence of symptoms correlated with more severe functional and radiographic abnormalities, and these 12 patients with CBD were being treated with corticosteroids prior to studying their BAL T-cell repertoire. Seventeen of the 28 patients with CBD were serially studied over a period of 4 yr. A group of 10 healthy individuals (age 43 6 2.9 yr; 5 men, 5 women; 9 never smokers, 0 current smokers, 1 former smoker) served as controls for the blood and BAL studies. Informed consent was obtained from each patient and volunteer, and the protocol was approved by the Human Subjects Institutional Review Board, National Jewish Medical and Research Center. Table 1 shows the age, gender, race, and smoking status for the patients and healthy controls in this study. Isolation and Initial Analysis of Mononuclear Cells from Peripheral Blood and BAL Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized blood by Ficoll–Hypaque density gradient separation, and the percentage of T cells expressing CD4 and CD8 are shown in Table 1. BAL was performed as previously reported (16), and the yield of white blood cells per milliliter and the percentages of lymphocytes, macrophages, neutrophils, and eosinophils in patients and controls are shown in Table 1. BAL lymphocytes from CBD patients had a significantly larger fraction of CD41 T cells and a smaller fraction of CD8 1 T cells compared with controls (Table 1). Especially considering the higher white-cell counts and the higher percentages of lymphocytes, CBD patients demonstrated a 9.8-fold increase in the absolute number of CD4 1 T cells in BAL compared with healthy controls. Beryllium lymphocyte proliferation tests were performed as previously described (15) in the CBD patients. The mean (6 SEM) peak stimulation indices for blood and BAL T cells in response to BeSO4 exposure were 24.5 6

TABLE 1

Characteristics of CBD patients and controls and initial analysis of cell subsets in blood and BAL* Characteristics

Age Gender (M/F) Race (C/AF/O)† Smoking status (CS/FS/NS)‡ Peripheral blood cells CD31 (%) CD31 expressing CD4 (%) CD31 expressing CD8 (%) Bronchoalveolar lavage cells WBC count/ml (3 104) Lymphocytes (%) Macrophages (%) Neutrophils (%) Eosinophils (%) CD31 (%) CD31 expressing CD4 (%) CD31 expressing CD8 (%)

CBD Patients (n 5 28)

Controls (n 5 10)

50 6 2.1 20/8 24/2/2 2/13/13

43 6 2.9 5/5 9/1/0 0/1/9

76 6 1.2 42 6 1.8 28 6 2.0

80 6 2.4 48 6 2.6 27 6 2.8

50.7 6 5.3§ 41 6 4.0i 57 6 3.9 1 6 0.5 ,1 95 6 1.1 79 6 2.6 12 6 1.7

14.6 6 1.1 22 6 4.3 76 6 4.6 2 6 0.8 ,1 95 6 0.9 60 6 4.3 28 6 3.3i

* Data are expressed as mean 6 SEM. † C 5 Caucasion; AF 5 African-American; O 5 other. ‡ CS 5 current smoker; FS 5 former smoker; NS 5 never smoker. § P , 0.001. i P < 0.01.

5.7 and 59.6 6 20.2, respectively. In studies at our institution, the mean stimulation index 6 2 SD for healthy controls was 1.9, which was used as a cutoff to indicate an abnormally elevated test. Human leukocyte antigen (HLA) typing was performed by standard serologic techniques (Immunological Associates of Denver, Denver, CO). Immunofluorescence Analysis of TCR Vb and Va Expression Mononuclear cells were analyzed by two-color immunofluorescence for TCR V region gene expression using monoclonal antibodes (mAb) directed to nine different TCR Vb receptors and two TCR Va receptors. Most BAL and blood samples were stained using biotinylated mAb directed against Vb2 (clone E22E7.2) (17), Vb3.1 (clone 8F10) (18, 19), Vb5.1 (clone LC4) (20), Vb6.7 (clone OT145) (21), Vb8.1/8.2 (clone MX8) (22), Vb12 (clone S511) (23), Vb13.1 (clone H131) (24), V b13.2 (clone H132) (24), Vb17 (clone E175F3) (17), V a2.3 (clone F1) (12), and Va12.1 (clone 6D6) (25). Anti-Vb mAb were obtained as follows: Vb2 and Vb17 (Immunotech, Marseille, France); Vb3.1, Vb5.1, Vb8.1/8.2, Vb12, Va2.3, and Va12.1 (T Cell Sciences, Cambridge, MA). The mAb to Vb13.1 and Vb13.2 were generated as described (24) and are available upon request. Streptavidin-phycoerythrin (Fisher Biotech, Pittsburgh, PA) was used as a second-step reagent for TCR staining, and cells were also double-stained with fluorescein isothiocyanate (FITC)-labeled CD3, CD4, and CD8 (all from Becton Dickinson, San Jose, CA). The lymphocyte population was identified using forward and 90-degree light-scatter patterns, and fluorescence intensity was ana-

Fontenot, Kotzin, Comment, et al.: T-cell Receptor Repertoire in Chronic Beryllium Disease

lyzed using an Epics Profile Cytometer (Coulter Electronics, Hialeah, FL) as previously described. Stimulation of BAL Cells with BeSO4 and Interleukin-2 Mononuclear cells derived from the BAL of 13 CBD patients were resuspended at a concentration of 2 3 106 cells/ ml in culture media (RPMI 1640 with 10% fetal calf serum, 2 mM L-glutamine, 50 U/ml penicillin, and 50 mg/ml streptomycin) and stimulated with BeSO4 at a concentration of 1 3 1025 M. After 72 h of culture, the stimulated cells were resuspended in fresh culture media with the addition of 25 U/ml recombinant interleukin (IL)-2 (Amgen, Thousand Oaks, CA), and the cultured cells were harvested at Day 7. Cells from four patients were cultured for

583

an additional seven days with the addition of fresh culture media and IL-2 and then analyzed on Day 10. Analysis of TCR V region expression on stimulated BAL cells was performed as described above for the analysis of the unstimulated BAL cells and PBMC with the exception that forward and 90-degree light-scatter patterns were used to gate on lymphocyte blasts rather than the smaller lymphocyte population (23, 26). Statistical Analysis Due to the non-Gaussian distribution of the data, we employed the Wilcoxon rank sum test within the CBD population and between the patients with CBD and normal control subjects (JMP®, Version 3; SAS Institute Inc., Cary, NC). Due to the large number of comparisons, a P value < 0.01 was used to determine statistical significance.

Results TCR Expression in Peripheral Blood and BAL T Cells of Patients with CBD and Control Subjects

Figure 1. TCR Vb repertoire in BAL compared with blood in four representative CBD patients who demonstrated evidence of an expansion (. 2-fold) in the BAL compared with the blood. Data are expressed as the mean percentage of CD4 1 T cells expressing a particular Vb. The asterisk is used to identify the expanded Vb in the individual patients.

Freshly isolated BAL and peripheral blood cells were obtained from patients and control subjects, and the percentage of CD41 T cells expressing particular V regions was determined by immunofluorescence staining and cytofluorographic analysis. Figure 1 shows representative examples of TCR repertoires for patients who demonstrated an expansion of at least one Vb subset in the BAL (defined as a 2-fold increase in the percentage of Vb-expressing cells in the BAL compared with blood). For example, Patient 1 showed an increased percentage of Vb8.11 T cells in the BAL compared with the blood CD4 population (13.2% versus 3.8%). In Patient 2, 12% of the CD41 T cells in BAL expressed Vb3 as compared with 5.6% in the blood. Patient 2 also demonstrated an expansion of Vb6.7 in the BAL compared with blood (6.5% versus 3.0%). Patient 3 demonstrated a Vb3 expansion with 10.6% of the CD4 1 T cells in the BAL expressing Vb3 compared with 2.0% in the blood, and Patient 4 was noted to have a Vb13.2 expansion (4.9% versus 0.4%). Overall, using this definition for T-cell subset expansion, 11 of the 28 CBD patients demonstrated expansions. One patient had three expansions and three others had two expansions each. In contrast, only one of the controls demonstrated one Vb5.1 expansion. Of the 16 T-cell subset expansions in CBD patients, five were Vb3, three expressed Vb13.2, and two expressed Vb6.7 or Vb8.1/8.2; Vb5.1, Vb12, Va2.3, and Va12.1 were each represented once. Figure 2 shows mean (6 SEM) levels of the TCR V region expression in the BAL and blood of all patients and healthy control subjects. Comparison of BAL versus blood demonstrates remarkable heterogeneity within the BAL repertoire in both patients and controls. Thus, for most Vb- and Va-expressing subsets, the levels in the BAL and blood were similar. The results also indicate that the BAL CD41 repertoire is not just a passive reflection of blood T cells. For example, both controls and patients showed an increase in the levels of Vb21 cells in blood compared with BAL (P , 0.001 for both controls and patients with CBD). In the control subjects, significant increases in the percentage of Vb31 and Vb171 cells were also seen in the blood

584

AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY VOL. 18 1998

compared with BAL. However, only CBD patients demonstrated increases in the mean levels of BAL V bexpressing subsets compared with blood. We observed a trend for an increase in the expression of Vb6.7 (4.8 6 0.5 versus 3.9 6 0.4%; P 5 0.035) and Vb13.2 (1.5 6 0.4 versus 0.8 6 0.2%; P 5 0.027) within the BAL as compared with blood of patients with CBD. We also compared the mean levels shown in Figure 2 in patients with CBD versus controls. As expected, the percentage of each of the subsets in blood was similar in both groups. However, a significantly greater expression of Vb31 cells in the BAL of patients with CBD compared with control subjects (5.3 6 0.7% versus 1.8 6 0.6%; P 5 0.005) was noted, as well as trends for increases in Vb6.7, Vb8.1, Vb13.2, and Vb17. Figure 3 shows differences in the percentage of Vb- or Va-expressing subsets in the BAL minus blood in each individual studied. A positive value reflects an increased percentage of a particular subset in BAL. If BAL T cells were a passive reflection of those in blood, we would expect the values to cluster around zero. Overall, the scatter was much greater in patients with CBD compared with healthy controls, related to a greater number of high positive values. Consistent with mean values shown above, the

Figure 2. TCR V region expressed in the blood and BAL of ten controls (A) and 28 CBD patients (B). Data are expressed as the mean 6 SEM percentage of CD41 T cells expressing a particular Vb or Va. Va mAb staining was performed in eight of the 28 CBD patients.

percentage of Vb21 cells was consistently higher in the blood compared with BAL in controls and patients, which is shown as negative values in Figure 3. Similar negative values were apparent for Vb3, but only in the controls. When we compared the BAL-versus-blood differences in patients and controls, we noted a significant difference for Vb31 cells (P 5 0.005) and a trend for Va12.1 (P 5 0.03). The largest positive difference (i.e., percentage in BAL greater than blood) in the control subjects was 3.3% (the one Vb5.1 expansion described above). If we apply this value as a cutoff to define expansions, 17 T-cell subset expansions were identified in the patients with CBD, and, as expected, a strong correlation was apparent with the expansions described above. The results in Figure 3 also suggest that our analysis did not miss large expansions in different patients with CBD that express Vbs not covered by the panel of anti-TCR mAb. Thus, for patients with CBD versus controls as a group, a trend for negative values in the subsets covered, caused by reciprocal changes from a large expansion, was not apparent. In addition, no individual patient with CBD showed multiple negative BALminus-blood percentages for the subsets analyzed. Presence of V Region Expansions in Relation to Clinical Variables Of the 11 CBD patients with T-cell subset expansions, six were exposed to beryllium while employed in the ceramics industry and five had worked in a nuclear weapons plant. Three of the five patients with Vb31 expansions had exposures in the ceramics industry. Thus there appeared to be no predilection for one type of exposure to be associated with the presence of an expansion or for particular Vb usage. Six of the 19 individuals initially diagnosed through screening programs had detectable V region expansions, compared with five of the nine patients diagnosed after symptom development. Corticosteroid therapy had been initiated in 12 patients with CBD with symptoms prior to enrollment in this study; overall, these individuals demonstrated more severe clinical, physiologic, and radiographic abnormalities. Half of these patients had detectable expansions, whereas six of the 16 asymptomatic patients also had expansions. There was no correlation between the duration of symptoms or corticosteroid treatment and the presence of a detectable expansion (data not shown). Longitudinal Studies of BAL TCR Repertoire in Patients with CBD Seventeen of the 28 patients with CBD underwent repeat BAL and TCR repertoire analysis during the study period. Eight of these patients were receiving corticosteroid treatment at the time of the subsequent sampling. Figure 4 shows representative longitudinal results for six patients who demonstrated skewing of Vb expression in the initial analysis. Subsets of Vb3, Vb6.7, and Vb8.1 are shown because these subsets encompassed most of the abnormalities found in the CBD population. Even though we observed some variability over time, the results indicate that the TCR Vb expansions in individual patients’ BAL persist. Eight of the 11 patients who demonstrated a particular Vb expansion at the time of the first evaluation under-

Fontenot, Kotzin, Comment, et al.: T-cell Receptor Repertoire in Chronic Beryllium Disease

585

Figure 3. Percentage of CD4 1 T cells expressing a particular TCR V region in the BAL minus the percentage in the blood of normal controls (A) and CBD patients (B). The solid line represents the mean of each V region analyzed. The dashed line (at 3.3%) represents the largest positive percent difference in the healthy controls.

went repeat analysis, and persistent Vb expansions (same Vb subset) were found in six of the eight patients. In addition, none of the patients with CBD who failed to show altered Vb3 expression in the BAL on first evaluation developed a Vb31 expansion upon serial analysis. Patient 6 in Figure 4 had a Vb3 expansion at the first analysis and continued to have an elevated Vb3 subset in the BAL compared with blood (6.7% versus 3.7%); however, it did not meet our definition of an expansion. Longitudinal changes in patients being treated with corticosteroids did not appear to be different compared with untreated patients (Figure 4). Overall, CBD patients analyzed serially demonstrated similar TCR V region repertoire alterations over time.

In Vitro Stimulation of T Cells with BeSO4 and IL-2 Previous studies have demonstrated that lymphocytes obtained from the BAL and from the blood of patients with CBD respond to beryllium in culture by proliferation and with the production of IL-2, IL-6, and tumor necrosis factor-a (8, 10, 27). BAL lymphocytes from 13 patients with CBD (including four of the 11 with BAL TCR Vb expansions) were stimulated in culture with BeSO4, followed by the addition of IL-2 on Day 3. After seven days of culture, the majority of viable cells were blasted, as determined by forward angle and 90-degree side-scatter light patterns. As shown in Figure 5, this short-term culture in BeSO 4 and IL-2 resulted in additional alterations of the TCR V b repertoire in some patients. The four CBD patients who

586

AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY VOL. 18 1998

Figure 4. Longitudinal studies of BAL TCR repertoire in CBD patients. These patients demonstrated altered TCR Vb expression (five with elevated Vb3 and one with elevated Vb8.1) at the time of the initial evaluation. The square, triangle, and circle represent the percentage of CD4 1 T cells expressing Vb3, Vb6.7, and Vb8.1, respectively, at different time points. The arrow represents the initiation of corticosteroids.

Figure 5. TCR repertoire of BAL CD41 T cells before and after in vitro stimulation with BeSO4 and IL-2. For clarity, only certain Vbs are shown. The percentages of CD4 1 T cells expressing a particular Vb are shown for Day 0 and after 7 d of culture and are connected by a solid line. The open circles represent those CBD patients with TCR Vb expansions at the time of the first evaluation. The open squares show those CBD patients who developed a TCR expansion after short-term culture with BeSO 4 and IL-2.

showed Vb expansions on initial evaluation expressed five different expansions. Three of the five TCR Vb expansions in the patients with CBD who had Vb expansions at baseline demonstrated additional increases in the percentage of cells expressing that Vb. For example, Patient 3 demonstrated a further 9.1% increase in the percentage of CD41 T cells expressing Vb3 (10.6% to 19.7%). However, there were also exceptions to this pattern, with some patients demonstrating no change in the percentage of a subset after stimulation and an occasional patient without an expansion at baseline who developed a particular Vb expansion after short-term culture. For example, one patient showed an increase from 4.5% to 22.4% in the percentage of CD41 T cells expressing Vb17 (Figure 5).

An asterisk indicates that this particular patient was evaluated at Days 0 and 14. A dagger marks one patient who developed a Vb17 expansion after short-term culture.

Fontenot, Kotzin, Comment, et al.: T-cell Receptor Repertoire in Chronic Beryllium Disease

Previous studies from our laboratories have demonstrated that BAL cells from healthy control subjects do not proliferate or blast in response to BeSO4 or IL-2 (28). Therefore, BAL cells from controls were not cultured in this study. HLA Typing of Patients with Vb Subset Expansions Differences in the TCR V regions expressed by expanded subsets could be explained at the level of antigen and/or class II MHC-presenting molecule. It seemed possible, therefore, that the Vb3 expansions identified in this group of patients with CBD were related to a common HLA haplotype. Table 2 compares the results of HLA-DR and -DQ serological typing for the five patients with Vb3 expansions and one patient with Vb8.1 expansion. No obvious association between HLA phenotype and alterations in the TCR Vb expression was observed, although the one patient with CBD with a Va2.3 expansion was typed as HLA-DR3. This association between HLA-DR3 and Va2.3 expansions has been previously observed by Grunewald and colleagues (12, 14) in sarcoidosis.

Discussion It has been estimated that 800,000 individuals in the United States have current or past beryllium exposure and are at risk for developing CBD (29). Chronic lung disease will develop in about 1 to 5% of these individuals (6), and most cases will not be apparent until years after leaving the workplace in which exposure to beryllium occurred. In addition to exposure, genetic susceptibility has been postulated to be an important variable in the immunopathogenesis of CBD. At least one component of this susceptibility is likely to control the quantity and/or quality of the immune response to beryllium. Considerable data suggest that CD41 T cells are critically involved in the disease process. Thus sensitization is detected by the ability of CD4 1 T cells to proliferate upon exposure to BeSO4 in culture (6, 15, 30), and the development of granulomatous inflammation in the lung is associated with the accumulation of CD41 T cells in BAL (1). The present TCR repertoire studies were initiated to provide insight into the nature of these infiltrating T cells, especially to identify subsets with

TABLE 2

Summary of Vb expansion and class II HLA type Patient

Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6

Class II HLA Type

DR7,13,52,53 DQ1,2 DR4,53 DQ3 DR4,9,52,53 DQ3 DR7,8,53 DQ2,7 DR6,7,52,53 DQ1,2 DR1,15 DQ3

Vb Expanded in BAL

% CD41 Cells Expressing Vb in BAL (% in Blood)

8.1

13.2 (3.8)

3, 6.7

12.0 (5.6)

3

10.6 (2.0)

3

7.4 (3.5)

3

16.3 (8.0)

3

10.2 (3.3)

587

skewed TCR expression and therefore T cells that may have responded to specific antigens. We used immunofluoresence staining to quantitate TCR expression, rather than semiquantitative polymerase chain reaction (PCR) techniques, in an attempt to increase the accuracy of quantitation and to decrease variability in longitudinal studies. Although a number of new anti-TCR mAb have been generated in the last few years (12, 17–25), our reagents still only covered about 30–35% of the CD41 TCR repertoire. Despite this drawback, we identified at least one BAL CD41 T-cell subset expansion in approximately 40% of the patients with CBD evaluated. It seems unlikely that our analysis missed large expansions that express Vbs not covered by the panel of anti-TCR mAb, especially if similar V regions were utilized in different patients. Thus reciprocal decreases in BAL subset percentages compared with blood in the same individual were not apparent. Although our panel of mAb could have missed other relatively small expansions, it seems likely that a more comprehensive panel of anti-TCR mAb would simply reinforce the heterogeneous T-cell response already identified. On the whole, TCR expression in the lungs of the majority of patients with CBD was heterogeneous and similar to that expressed by blood T cells in the same individuals. This was not unexpected. Prior studies in sarcoidosis have suggested that only a subset of T cells are likely to be activated and expanded in the BAL (28). A similar phenomenon seems likely to occur in CBD. This heterogeneous repertoire may reflect the influx of nonspecific T cells to the site of lung inflammation. For example, studies of mice after immunization with myelin basic protein demonstrated little enrichment of the pathogenic T-cell subset in inflammatory brain lesions (31). Instead, T cells at the site of pathology expressed a repertoire similar to lymphoid tissue, with the pathologic subset being obscured by the influx of nonspecific T cells. In prior studies of T cells in patients with sarcoidosis, clonal T-cell populations and skewed TCR expression could be regularly demonstrated only after BAL CD41 T cells were cultured with IL-2 to expand previously activated T cells (28). T-cell responses to numerous different antigens or use of different presenting molecules in the lung could also contribute to a heterogeneous BAL T-cell repertoire in patients, perhaps reflecting the ability of beryllium to complex with multiple different proteins or peptides. The type of beryllium exposure, presence or duration of symptoms, or treatment with corticosteroids appeared to have no effect on either the presence of a BAL T-cell subset expansion or V region expressed. We defined an expansion as a 2-fold increase in the percentage of a particular Vb or Va subset in BAL compared with blood of the same individual. TCR expression of blood T cells in patients with CBD appeared to be altered little and provided a reasonable basis for comparison with the BAL TCR repertoire. This definition also allowed for known differences in baseline T-cell V region expression among different individuals (18, 21, 23–25, 28, 32). We also reanalyzed the results using the mean percentage 6 3 SD for the corresponding subset in control BAL. Using this cutoff to define an expansion, 28 expansions were identified in 18 CBD patients compared with none in controls.

588

AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY VOL. 18 1998

Although the overlap in identified expansions was extensive, our initial definition for expansion was more stringent. In addition, we compared the percentage of CD4 1 T cells expressing a particular Vb or Va in the BAL minus blood in both the patients with CBD and healthy control subjects. The largest positive percent difference in the control subjects was 3.3%. In contrast, there were 17 subsets in the patients with CBD with a BAL-minus-blood percentage difference greater than 3.3%. As expected, comparison of expansions defined by this approach showed a strong correlation with those expansions defined by the 2-fold increase in the percentage in BAL versus blood. Overall, these considerations appear to support the approach used to define expansions in the BAL of patients with CBD. In 11 of 28 patients studied, we identified 16 BAL T-cell subset expansions. These expansions reflect large increases in the absolute number of a particular T-cell subset, considering that the CBD patients had an average 9.8-fold increase in absolute number of CD4 1 T cells in the BAL compared with the control group. In some patients, we estimated a 30- to 50-fold increase in the number of cells expressing a particular TCR Vb. About one-third of the expansions expressed Vb3, which is much greater than expected based on the percentage of T cells in this subset. For example, in past studies, the mean percentage of CD41 T cells expressing Vb3 was about 5% (26, 28, 32), which is close to the levels found in the blood of patients and control subjects in the present study. The increased percentage of Vb31 cells in the BAL of patients with CBD was even more remarkable considering that Vb31 cells appeared to be relatively excluded from the BAL of healthy controls. Indeed, this selective decrease in the BAL of control subjects suggested that the number of patients with CBD with increased percentages of Vb31 cells was underestimated by our relatively stringent definition of expansion. The relevance of the increased percentages of Vb31 T cells (or other subsets) was further strengthened by the persistence of most expansions in patients followed longitudinally and by the further expansion of particular Vb-expressing subsets after in vitro stimulation with BeSO4. The relatively frequent increase in Vb3 expression among patients suggests that a similar peptide/beryllium complex or other forms of beryllium complex may be involved in the stimulation of T cells in the lungs of these patients. It is also important to emphasize that our set of anti-TCR mAb covered only a limited portion of the CD4 repertoire (see above), which could have contributed to our not finding expansions in a number of patients. In addition, immunofluorescence staining for the percentage of cells may have missed small but expanded T-cell populations within a particular Vb or Va subset that express the same or similar TCR complementarity determining region 3. Our studies also provided a description of the TCR repertoire of BAL T cells in healthy control subjects, which may reflect T cells that remain after responses to respiratory stimuli or perhaps T cells that comprise a resident lung population. In general, we found that the repertoire of BAL CD41 T cells in the healthy controls was similar to that in the circulating population. We did note a relatively

consistent exclusion of Vb21 and Vb31 T cells from the BAL. These findings are different compared with one previous report in which semiquantitative PCR techniques were used to quantitate TCR expression of BAL T cells in healthy control subjects (33). The previous study did not separate CD4 and CD8 populations. The difference in results and the reason for the relative exclusion of certain T-cell subsets from BAL are unexplained at this time. T cells from patients with CBD respond to BeSO4 in a class II MHC-restricted manner (1), and we hypothesized that the patients with Vb31 T-cell expansions might share a common class II MHC haplotype and therefore share a similar presenting MHC/antigen complex. However, HLADR and -DQ types varied considerably in the patients with CBD with altered Vb3 expression, and common HLA molecules were not identified. It is possible that molecular typing might disclose some similarities among the different DR or DQ molecules expressed by these patients. More importantly, a previous study suggested that nearly all patients with CBD may express a particular HLA-DP (DPB1*0201) molecule compared with the general population (34). We did not examine DP expression in our patients, and HLADP may not be in linkage disequilibrium with HLA-DR or -DQ. The best demonstration of the potential importance of HLA in granulomatous lung disease is in sarcoidosis. Grunewald and associates (12, 14) found that patients carrying HLA-DR3 had increased percentages of CD4 1 T cells expressing Va2.3 selectively in the BAL during periods of active disease. We found one patient who had a Va2.3 expansion, and this patient expressed a haplotype encoding HLA-DR3. Several previous studies have examined the TCR repertoire of BAL T cells in patients with sarcoidosis, a granulomatous lung disease of unknown etiology (12–14, 26, 28, 33). Similar to our findings in CBD, patients demonstrated very heterogeneous repertoires and some were noted to have Vb skewing and clonal expansions. In a number of patients, skewing and clonal expansions were not apparent until BAL T cells were cultured in IL-2. Among the expanded Vb subsets and clones in sarcoidosis patients, TCR expression was remarkably diverse, although there was a suggestion for increased usage of Vb8 and Va2.3 (in HLA-DR3 individuals) in certain studies (12–14). In the present study, we identified two patients with CBD with Vb8 expansions and only one expressing Va2.3, and we found an increased number of patients with CBD with Vb31 T-cell expansions. These results suggest that the TCRs expressed by expansions in CBD and therefore the antigens recognized in the lungs are distinct in these two diseases with similar lung pathology. Together, our results suggest that there is a selective expansion or selective accumulation of certain CD41 T-cell subsets in the lungs of patients with CBD, and it seems reasonable to speculate that this is related to local stimulation by an antigen that involves beryllium. The nature of such an antigen is unknown. It has been hypothesized that beryllium may bind to different self peptide(s), which are recognized as foreign when presented by class II MHC molecules. Our findings showing selective expansions that express different Vbs in different patients appear to be most consistent with conventional antigen (peptide) rec-

Fontenot, Kotzin, Comment, et al.: T-cell Receptor Repertoire in Chronic Beryllium Disease

ognition. The variability of TCR V region usage among different patients with CBD makes stimulation by the same superantigen(s) unlikely. However, prior to sequencing the junctional regions of the TCR expressed by expansions and determining whether clonal T-cell expansions are present, we cannot exclude the possibility that beryllium combines with self peptide and class II MHC in some way to stimulate T cells as a superantigen. The T-cell expansions identified in the present studies should provide the tools necessary to understand how beryllium causes T-cell stimulation and T-cell-mediated disease. Acknowledgments: This work is supported by U.S. Public Service NIH SCOR Grant HL-27353 and General Clinical Research Center Grant M01RR0051. The authors thank Patricia Schwitters for assistance with BAL and blood preparation; Mary Solida, RN, for assistance with CBD patient care; and Elaine Daniloff, MSPH, and Becki Bucher-Bartelson, Ph.D., for assistance with statistical analysis.

References 1. Saltini, C., K. Winestock, M. Kirby, P. Pinkston, and R. G. Crystal. 1989. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N. Engl. J. Med. 320:1103–1109. 2. Newman, L. S. 1996. Immunology, genetics, and epidemiology of beryllium disease. Chest 109(Suppl.):S40–S43. 3. Rose, C. S., and L. S. Newman. 1993. Hypersensitivity pneumonitis and chronic beryllium disease. In Interstitial Lung Disease, 2nd ed. M. I. Schwarz and T. E. King, Jr., editors. Mosby Year Book, St. Louis. 213–252. 4. Kriebel, D., J. D. Brain, N. L. Sprince, and H. Kazemi. 1988. The pulmonary toxicity of beryllium. Am. Rev. Respir. Dis. 137:464–473. 5. Freiman, D. G., and H. L. Hardy. 1970. Beryllium disease: the relation of pulmonary pathology to the clinical course and prognosis based on a study of 130 cases from the U.S. Beryllium Case Registry. Hum. Pathol. 1:25–44. 6. Newman, L. S., K. Kreiss, T. E. King, Jr., S. Seay, and P. A. Campbell. 1989. Pathologic and immunologic alterations in early stages of beryllium disease: re-examination of disease definition and natural history. Am. Rev. Respir. Dis. 139:1479–1486. 7. Newman, L. S., C. Bobka, B. Schumacher, E. Daniloff, B. Zhen, M. Mroz, and T. E. King, Jr. 1994. Compartmentalized immune response reflects clinical severity of beryllium disease. Am. J. Respir. Crit. Care Med. 150: 135–142. 8. Rossman, M. D., J. A. Kern, J. A. Elais, M. R. Cullen, P. E. Epstein, O. P. Preuss, T. N. Markham, and R. P. Daniele. 1988. Proliferative response of bronchoalveolar lymphocytes to beryllium. Ann. Intern. Med. 108:687–693. 9. Epstein, P. E., J. H. Dauber, M. D. Rossman, and R. P. Daniele. 1982. Bronchoalveolar lavage in a patient with chronic berylliosis: evidence for hypersensitivity pneumonitis. Ann. Intern. Med. 97:213–216. 10. Tinkle, S. S., L. A. Kittle, B. A. Schumacher, and L. S. Newman. 1997. Beryllium induces IL-2 and IFN-g in berylliosis. J. Immunol. 158:518–526. 11. Newman, L. S., and K. Kreiss. 1992. Nonoccupational beryllium disease masquerading as sarcoidosis: identification by blood lymphocyte proliferation response to beryllium. Am. Rev. Respir. Dis. 145:1212–1214. 12. Grunewald, J., O. Olerup, U. Perrson, M. B. Ohrn, H. Wigzell, and A. Eklund. 1994. T-cell receptor variable region gene usage by CD41 and CD81 T cells in bronchoalveolar lavage fluid and peripheral blood of sarcoidosis patients. Proc. Natl. Acad. Sci. USA 91:4965–4969. 13. Moller, D. R., K. Konishi, C. Saltini, M. Kirby, and R. G. Crystal. 1988. Bias toward use of a specific T cell receptor b-chain variable region in a subgroup of individuals with sarcoidosis. J. Clin. Invest. 82:1183–1191. 14. Grunewald, J., C. H. Janson, A. Eklund, M. Ohrn, O. Olerup, U. Perrson, and H. Wigzell. 1992. Restricted Va2.3 gene usage by CD41 T lymphocytes in bronchoalveolar lavage fluid from sarcoidosis patients correlates with HLA-DR3. Eur. J. Immunol. 22:129–135. 15. Mroz, M. M., K. Kreiss, D. C. Lezotte, P. A. Campbell, and L. S. Newman.

16.

17.

18. 19.

20. 21. 22.

23. 24.

25.

26. 27.

28.

29. 30. 31. 32.

33. 34.

589

1991. Reexamination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease. J. Allergy Clin. Immunol. 88:54–60. The BAL Cooperative Group Steering Committee. 1990. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis and selected comparison groups. Am. Rev. Respir. Dis. 141(Suppl.):S168– S202. Romagne, F., L. Besnardeau, and B. Malissen. 1992. A versatile method to produce antibodies to human T cell receptor V beta segments: frequency determinations of human V beta 21 T cells that react with toxic-shock syndrome toxin-1. Eur. J. Immunol. 22:2749–2752. Donahue, J. P., N. S. Ricalton, C. E. Behrendt, C. Rittershaus, S. Calaman, P. Marrack, J. W. Kappler, and B. L. Kotzin. 1994. Genetic analysis of low V beta 3 expression in humans. J. Exp. Med. 179:1701–1706. Calaman, S. D., G. R. Carson, L. D. Henry, J. S. Kubinec, R. E. Kuestner, A. Ahmed, E. M. Wilson, A. Y. Lin, C. W. Ritterhaus, and H. C. Marsh, Jr. 1993. Characterization of monoclonal antibodies specific for the Vb3 family of the T cell receptor generated using soluble TCR b-chain. J. Immunol. Methods 164:233–244. Yssel, H., D. Blanchard, A. Boylston, J. DeVries, and H. Spits. 1986. T cell clones which share T cell receptor epitopes differ in phenotype, function, and specificity. Eur. J. Immunol. 16:1187–1193. Posnett, D. N., C. Y. Wang, and S. M. Friedman. 1986. Inherited polymorphism of the human T-cell antigen receptor detected by a monoclonal antibody. Proc. Natl. Acad. Sci. USA 83:7888–7892. Carrel, S., P. Isler, M. Schreyer, A. Vacca, S. Salvi, L. Giuffre, and J. P. Mach. 1986. Expression on human thymocytes of the idiopathic structures (Ti) from two leukemia T cell lines Jurkat and HPB-ALL. Eur. J. Immunol. 16:649–652. Kappler, J., B. Kotzin, L. Herron, E. W. Gelfand, R. D. Bigler, A. Boylston, S. Carrel, D. N. Posnett, Y. Choi, and P. Marrack. 1989. Vb-specific stimulation of human T cells by staphylococcal toxins. Science 244:811–813. Choi, Y. W., B. Kotzin, J. Lafferty, J. White, M. Pigeon, R. Kubo, J. Kappler, and P. Marrack. 1991. A method for production of antibodies to human T-cell receptor b-chain variable regions. Proc. Natl. Acad. Sci. USA 88:8357–8361. DerSimonian, H., H. Band, and M. B. Brenner. 1991. Increased frequency of T cell receptor V alpha 12.1 expression on CD81 T cells: evidence that V alpha participates in shaping the peripheral T cell repertoire. J. Exp. Med. 174:639–648. [Published erratum appears in J. Exp. Med. 1991; 174, following 1286.] Forrester, J. M., L. S. Newman, Y. Wang, T. E. King, Jr., and B. L. Kotzin. 1993. Clonal expansion of lung Vd11 T cells in pulmonary sarcoidosis. J. Clin. Invest. 91:292–300. Bost, T. W., D. W. H. Riches, B. Schumacher, P. C. Carré, T. Z. Khan, J. A. B. Martinez, and L. S. Newman. 1994. Alveolar macrophages from patients with beryllium disease and sarcoidosis express increased levels of mRNA for tumor necrosis factor-a and interleukin-6 but not interleukin1b. Am. J. Respir. Cell Mol. Biol. 10:506–513. Forrester, J. M., Y. Wang, N. Ricalton, J. E. Fitzgerald, J. Loveless, L. S. Newman, T. E. King, and B. L. Kotzin. 1994. TCR expression of activated T cell clones in the lungs of patients with pulmonary sarcoidosis. J. Immunol. 153:4291–4302. Cullen, M. R., M. Ohrn, and J. R. Kominsky. 1986. Chronic beryllium disease in the United States. Sem. Respir. Med. 7:203–209. Kreiss, K., L. S. Newman, M. Mroz, and P. A. Campbell. 1989. Screening blood test identifies subclinical beryllium disease. J. Occup. Med. 31:603– 608. Bell, R. B., J. W. Lindsey, R. Sobel, S. Hodgkinson, and L. Steinman. 1993. Diverse T cell receptor Vb gene usage in the central nervous system in experimental allergic encephalomyelitis. J. Immunol. 150:4085–4092. Fitzgerald, J. E., N. S. Ricalton, A. C. Meyer, S. G. West, H. Kaplan, C. Behrendt, and B. L. Kotzin. 1995. Analysis of clonal CD81 T cell expansions in normal individuals and patients with rheumatoid arthritis. J. Immunol. 154: 3538–3547. Forman, J. D., J. T. Klein, R. F. Silver, M. C. Liu, B. M. Greenlee, and D. R. Moller. 1994. Selective activation and accumulation of oligoclonal Vb-specific T cells in active pulmonary sarcoidosis. J. Clin. Invest. 94:1533–1542. Richeldi, L., R. Sorrentino, and C. Saltini. 1993. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science 262:242–244.